Close Navigation
About ArixStrategy
OverviewInvestment CaseNewsResultsDocumentsEventsCalendarAnalystsStock infoContact
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

Insights

Here you will find insights from our team and contributions from leading biotech entrepreneurs. We plan to feature a mix of articles, thoughts and commentary around our investments, as well as news and trends in the biotech industry.

All InsightsBlogPodcastVideo
blog

9th November 2020

Arix’s first M&A exit: VelosBio to be acquired by Merck for $2.75bn in cash

blog

8th July 2020

VelosBio closes $137m Series B

blog

5th May 2020

Amplyx CEO on COVID-19 and Fungal Superinfections

blog

20th June 2019

'EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment' - Artios CEO interviewed by Labiotech

Arix Bioscience

About Arix

The Team

Portfolio

Insights

News & Events

Contact

Investor Relations

Results Centre

Financial Calendar

Regulatory News

Document Library

Analysts & Advisors

Shareholder Information

Meta

Privacy Policy

Terms of use

Cookie Policy

Stay up to date

Sign up to receive regulatory news and results

Subscribe
Arix Bioscience
linkedintwitter

Arix Bioscience plc, registered in England and Wales with company number 09777975

Registered office: Duke Street House, 50 Duke Street, London, W1K 6JL, United Kingdom

Website by Ether